Anti-CD20 monoclonal antibody (Rituximab) treatment for hepatitis c-negative therapy-resistant essential mixed cryoglobulinemia with renal and cardiac failure

被引：40

作者：

Ghijsels, E

Lerut, E

Vanrenterghem, Y

Kuypers, D

机构：

[1] Univ Hosp Leuven, Dept Med, Div Nephrol & Renal Transplantat, Louvain, Belgium

[2] Univ Hosp Leuven, Dept Morphol & Mol Pathol, Louvain, Belgium

来源：

AMERICAN JOURNAL OF KIDNEY DISEASES | 2004年 / 43卷 / 05期

关键词：

rituximab; anti-CD20; antibodies; essential cryoglobulinemia;

D O I：

10.1053/j.ajkd.2003.12.057

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

A case of hepatitis C virus (HCV)-negative essential mixed cryoglobulinemia with initial skin, joint, and liver involvement, complicated by severe renal and cardiac failure and resistant to corticosteroid therapy, plasmapheresis, chlorambucil, and cyclophosphamide is presented. Treatment with an anti-CD20 monoclonal antibody (rituximab) induced a persistent recovery of renal and cardiac function, disappearance of skin and joint lesions, and disappearance of cryoglobulins. In a 24-month follow-up period, our patient remains in remission and free of symptoms.

引用

页数：5

共 12 条

[1] Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab) [J].